Haleon plc (NYSE:HLN – Get Free Report) has received a consensus rating of “Buy” from the six brokerages that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $10.95.
A number of equities research analysts recently weighed in on HLN shares. Morgan Stanley lifted their price objective on shares of Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a report on Friday, September 20th. UBS Group raised shares of Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st.
Get Our Latest Research Report on Haleon
Haleon Stock Performance
Institutional Investors Weigh In On Haleon
Several hedge funds have recently modified their holdings of the business. Fortitude Family Office LLC bought a new position in Haleon in the third quarter worth approximately $28,000. Toronto Dominion Bank lifted its stake in shares of Haleon by 3,470.0% during the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after purchasing an additional 3,470 shares during the last quarter. Cultivar Capital Inc. purchased a new position in Haleon in the second quarter valued at about $40,000. Prospera Private Wealth LLC purchased a new position in Haleon in the third quarter valued at about $57,000. Finally, BOKF NA raised its holdings in Haleon by 68.8% in the second quarter. BOKF NA now owns 6,972 shares of the company’s stock worth $58,000 after purchasing an additional 2,842 shares in the last quarter. Hedge funds and other institutional investors own 6.67% of the company’s stock.
About Haleon
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
See Also
- Five stocks we like better than Haleon
- How to Invest in the FAANG Stocks
- Dow Jones: A Relevant Benchmark or a Relic of the Past?
- Insider Trades May Not Tell You What You Think
- 3 Big-Name Stocks Just Announced Big-Time Dividend Increases
- What Investors Need to Know About Upcoming IPOs
- Market Overreaction: 2 Stocks to Buy on the Way Down
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.